

HEPATITIS TODAY

Meeting the Challenges of a Silent Killer — Hepatitis B

Selected Readings

Expanded treatment choices and strategies for improved management of CHB

- Berg T, Moller B, Trinh H, et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV). Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy. Abstract 76.
- Buti M, Hadziyannis S, Mathurin P, et al. Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis. Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy. April 23-27, 2008.
- Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. *Ann Intern Med.* 2007;147(11):745-754.
- Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA.* 2006;295:65-73.
- Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. *Semin Liver Dis.* 2004; 24(Suppl 1):45-53.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. *J Hepatol.* 2009;50:227-242.
- Hadziyannis SJ, Costamena A, Laras A, Hadziyannis E. Predictors/determinants of sustained virological response (SVR) and of HBsAg loss following long term adefovir dipivoxil (ADV) therapy in HBeAg-negative chronic hepatitis (CHB). Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 874.
- Han SB, Chang T, Chao Y, et al. Five years of continuous entecavir for nucleoside-naïve HBeAg(+) chronic hepatitis B: results from study ETV-901. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 893.
- Heathcote E, Gane EJ, deMan RA, et al. Two-year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 158.
- Hui C-K, Zhang H-Y, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. *J Hepatol.* 2008;48(5):714-720.
- Jacobson IM. Combination therapy for chronic hepatitis B: ready for prime time? *J Hepatol.* 2008;48(5):687-691.
- Keeffe EB, Dieterich DT, Han SB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. 2008 Update. *Clin Gastroenterol Hepatol.* 2008;6:1315-1341.
- Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: preventing, detecting, and managing viral resistance. *Clin Gastroenterol Hepatol.* 2008;6:268-274.
- Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. *N Engl J Med.* 2007;357(25):2576-2588.
- Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. *Ann Intern Med.* 2007;147(1):58-61.
- Lau GK, Leung N, Hui CK, et al. Clevudine was superior to lamivudine in the patients with HBeAg (+) chronic hepatitis B. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 911.
- Lee WM. Hepatitis B virus infection. *N Engl J Med.* 1997;337(24):1733-1745.
- Leung N, Peng CY, Sollano J, et al. Entecavir (entecavir) results in higher HBV DNA reduction versus adefovir (adefovir) in antiviral-naïve HBeAg(+) adults with high HBV DNA: week 96 results (E.A.R.L.Y. Study). Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy. April 23-27, 2008.
- Manns M, Jeffers L, Dalekos T, et al. The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naïve and LAM-experienced subjects treated for chronic hepatitis B (CHB). Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy. Abstract 74.

Selected Readings (continued)

Marcellin P, Brunetto M, Bonino F, et al. In patients with HBeAg-negative chronic hepatitis B HBsAg serum levels early during treatment with peginterferon alfa-2a predict HBsAg clearance 4 years post-treatment. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 919.

Marcellin P, Buti M, Krastev Z, et al. Two-year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (Study 102), preliminary analysis. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 146.

Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med*. 2008;359(23):2442-2455.

Marcellin P, Piratvisuth T, Brunetto M, et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD), but not by lamivudine: results of 4-year follow-up. Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy. Abstract 103.

Schollmeyer J, Lutgehetmann M, Volz T, et al. Combination of entecavir and tenofovir as a rescue therapy is safe and highly efficient in cirrhotic HBV mono-infected patients with the history of multiple previous treatment failures. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 985.

US Centers for Disease Control and Prevention. Screening for chronic hepatitis B among Asian/Pacific Islander populations—New York City, 2005. *MMWR*. 2006;55(18):505-509. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5518a2.htm>. Accessed January 17, 2009.

US Centers for Disease Control and Prevention. FAQs for health professionals. overview and statistics: hepatitis B. Available at: <http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm>. Accessed January 20, 2009.

Van Bömmel F, De Man RA, Petersen J, et al. A multicenter analysis of antiviral response after 1 year of tenofovir monotherapy in HBV-monoinfected patients with prior nucleos(t)ide analogue experience. Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy. Abstract 73.

Yao GB, Xu DZ, Ren H, et al. Three years of continuous entecavir treatment in Chinese patients who had previously failed lamivudine: results from studies ETV-056 and ETV-050. Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy. Abstract 715.

Yurdaydin C, Idilman R, Cevik E, et al. Adefovir treatment of entecavir resistance in patients with lamivudine-refractory chronic hepatitis B. Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy.

REVEAL data support link between HBV and HCC

Chen CJ, Iloeje UH, Yang HI. HBV DNA levels and outcomes in chronic hepatitis B. Program and abstracts of Management of Hepatitis B: An NIH Consensus Conference. October 20-22, 2008. Bethesda, Maryland.

Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA*. 2006;295(1):65-73.

Chen CJ, Yang HI, Su J, et al. Serial monitoring of viral load and serum alanine aminotransferase level and the risk of hepatocellular carcinoma (HCC): R.E.V.E.A.L.-HBV study update. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL 2008). Milan, Italy. April 23-27, 2008.

Di Bisceglie AM. Hepatitis B and liver cancer. Program and abstracts of Management of Hepatitis B: An NIH Consensus Conference. October 20-22, 2008; page 35. Bethesda, Maryland.

Goebel T, Heinzel-Pleines U, Poremba C, et al. Usefulness of liver biopsy in chronic HBV with normal transaminases in a European setting: high prevalence of advanced liver fibrosis and cirrhosis. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 973.

Heathcote E, Marcellin P, Jacobson IM, et al. Limited value of single ALT determination for assessing chronic hepatitis B. 59th Annual Meeting of the American Association for the Study of Liver Disease (AASLD); October 31–November 4, 2008; San Francisco, California. Abstract 850.

Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. *Gastroenterology*. 2006;130(3):678-686.

Yuan HJ, Yuen MF, Ka-Ho Wong D, Sablon E, Lai CL. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. *J Viral Hepat*. 2005;12(4):373-379.

Office of Minority Health releases strategies to address HBV in AA/NHOPI communities

US Department of Health and Human Services. The Office of Minority Health releases strategies to address chronic hepatitis B in Asian American, Native Hawaiian and Other Pacific Islander communities. Press release; December 16, 2008. Available at: <http://www.omhrc.gov/templates/content.aspx?ID=7304&lvl=1&lvlID=10>. Accessed January 18, 2009.

US Department of Health and Human Services, Office of Minority Health. Goals and Strategies to Address Chronic Hepatitis B in Asian American, Native Hawaiian and Other Pacific Islander Populations. Available at: <http://www.omhrc.gov/templates/content.aspx?ID=7245&lvl=2&lvlID=190>. Accessed January 18, 2009.

CDC issues new guidelines for HBV screening

Keeffe EB, Dieterich DT, Han SB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 Update. *Clin Gastroenterol Hepatol*. 2008;6:1315-1341.

Lok ASF, McMahon BJ. Chronic hepatitis B: AASLD practice guidelines. *Hepatology*. 2007;45:507-39.

US Centers for Disease Control and Prevention. Screening for chronic hepatitis B among Asian/Pacific Islander populations—New York City, 2005. MMWR. 2006;55(18):505-509. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5518a2.htm>. Accessed January 17, 2009.

US Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR. 2008;57(RR-8):1-20. Available online at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm>. Accessed January 17, 2009.

US Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis—United States, 2006. In: CDC Surveillance Summaries, March 21, 2008. MMWR. 2008;57(No. SS-2). Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5702a1.htm>. Accessed January 17, 2009.

NIH Consensus Development Conference ignites controversy on the management of HBV

Lang L. NIDDK to establish Hepatitis B Clinical Research Network. *Gastroenterology*. 2008;134:7.

Liaw Y-F, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med*. 2004;351:1521-1531.

Shamliyan TA, MacDonald R, Shaikat A, Taylor BC, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. *Ann Intern Med*. 2009;150:111-124.

Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B. *Ann Intern Med*. 2009;150:104-110.

University of Pittsburgh Graduate School of Public Health. GSPH receives \$11 million to coordinate Hepatitis B Clinical Research Network. Press release, January 29, 2009. Available at: <http://www.publichealth.pitt.edu/news.php?id=73>. Accessed February 20, 2009.

US Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR. 2008;57(RR-8):1-20. Available online at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm>. Accessed January 17, 2009.

2008 Update on resistance to HBV therapies

Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. *Semin Liver Dis*. 2006;26(2):162-170.

Corte-Real RM, Calinas F, Rodrigues B, et al. Hepatitis B virus resistance patterns in chronic infected patients. Program and abstracts of the Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies; February 14-16, 2008; Paris, France. Abstract 12.

Fung SK, Mazzulli T, El-Kashab M, et al. Lamivudine-resistant mutation among treatment-naïve hepatitis B patients is common and may be associated with treatment failure. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 888.

Hézode C, Chevaliez S, Dhalluin-Venier V, et al. The combination of lamivudine and adefovir prevents both lamivudine and adefovir resistance in patients with chronic hepatitis B. Program and abstracts of the Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies; February 14-16, 2008, Paris, France. Poster 24.

Keeffe EB, Dieterich DT, Han SB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. *Clin Gastroenterol Hepatol*. 2008;6:1315-1341.

Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: preventing, detecting, and managing viral resistance. *Clin Gastroenterol Hepatol*. 2008;6:268-274.

Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. *Hepatology*. 2007;46:254-265.

Ludwig AD, Goebel T, Adams O, et al. Primary resistance mutations against nucleos(t)ide analogues in treatment naïve patients with HBV-infection. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 884.

Olivero A, Ciancio A, Gaia S, et al. Analysis of resistance mutations patterns in chronic hepatitis B patients treated with lamivudine and adefovir. Program and abstracts of the Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies; February 14-16, 2008; Paris, France. Poster 45.

Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding on versus switching to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. *Hepatology*. 2007;45:307-313.

Snow-Lampart A, Chappell BJ, Curtis M, et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg QD. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 977.

Selected Readings (continued)

Tenney DJ, Pokornowski KA, Rose RE, et al. Long-term resistance profile of entecavir in nucleoside-naïve patients with chronic hepatitis B from worldwide and Japanese development programs. Program and abstracts of the Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies; February 14-16, 2008; Paris, France. Poster 55.

Tenney DJ, Pokornowski, Rose RE, et al. Long-term resistance profile of entecavir in lamivudine-refractory patients with chronic hepatitis B from worldwide and Japanese development programs. Program and abstracts of the Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies; February 14-16, 2008; Paris, France. Poster 56.

Benefits and risks of combination therapy for HBV (SIDEBAR)

Hui CK, Zhang HY, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. *J Hepatol*. 2008;48(5):714-720.

Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. *J Hepatol*. 2007;46(suppl 1):S191.

Lampertico P, Viganò M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. *Gastroenterology*. 2007;133(5):1445-1451.

Lau GK, Piravisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. *N Engl J Med*. 2005;352:2682-2695.

Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. *Hepatology*. 2006;43:1385-1391.

Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. *Hepatology*. 2007;45(2):307-313.

Reijnders J, de Mann R, Pas S, et al. Entecavir: a rescue therapy for chronic hepatitis B patients with a limited virological response to adefovir. *Hepatology*. 2007;46:660A.

Sung JJ, Lai HY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. *J Hepatol*. 2008;48(5):728-735.

Terrault NA. Benefits and risks of combination therapy for hepatitis B. Program and abstracts of the NIH Consensus Development Conference: Management of Hepatitis B. October 20-22, Bethesda, Maryland.

Van Boemmel F, Trojan J, Feucht HH, et al. Tenofovir shows limited efficacy in treatment of HBV infections resistant against adefovir. *Hepatology*. 2007;46:664A.

Distribution of chronic HBV infection worldwide, 2006 (SIDEBAR)

McMahon BJ. Natural history of hepatitis B—clinical implications. *Medscape J Med*. 2008;10(4):91.

US Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic hepatitis B infection. *MMWR Recomm Rep*. 2008;57(RR-8):1-20.

World Health Organization. Hepatitis B. Geneva, Switzerland: World Health Organization; 2000. Available at <http://www.who.int/mediacentre/factsheets/fs204/en>. Accessed March 16, 2009.